Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter...

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Juvenile generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting neuromuscular junctions.
• Refractory anti-acetylcholine receptor (AChR) antibody-positive gMG in adolescents presents significant unmet therapeutic needs.
• Eculizumab, a terminal complement C5 inhibitor, offers a targeted approach to complement-mediated pathology in gMG.

Purpose of the Study:

• To evaluate the efficacy and safety of eculizumab in adolescents with refractory AChR antibody-positive gMG.
• To assess the impact of eculizumab on disease severity and daily functioning.
• To analyze the pharmacokinetic and pharmacodynamic profiles of eculizumab in this patient population.

Main Methods:

• A phase 3, open-label, multicenter study (NCT03759366) enrolled adolescents aged 12-17 years with refractory gMG.
• Patients received eculizumab induction followed by maintenance dosing for up to 26 weeks.
• Efficacy was measured by changes in Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores, among other endpoints.

Main Results:

• Eleven adolescents were enrolled, with 10 completing the study. Significant reductions in QMG and MG-ADL scores were observed by week 26.
• Primary and secondary efficacy endpoints met statistical significance and were sustained throughout the study period.
• Complete terminal complement inhibition was achieved and maintained, with all treatment-emergent adverse events being mild to moderate and primarily unrelated to eculizumab.

Conclusions:

• Eculizumab demonstrated significant efficacy in reducing disease burden in adolescents with refractory AChR antibody-positive gMG.
• The drug was well-tolerated, indicating a favorable safety profile in this population.
• Eculizumab represents a promising therapeutic option for juvenile gMG.